Skip to main content
Clinical Trials/NCT06347393
NCT06347393
Active, Not Recruiting
N/A

Transgender and GENdEr diverSe Individuals Screening for Breast Cancer: the GENESIS Study

Fondazione Policlinico Universitario Agostino Gemelli IRCCS1 site in 1 country1,600 target enrollmentMay 1, 2024
ConditionsBreast Cancer

Overview

Phase
N/A
Intervention
Not specified
Conditions
Breast Cancer
Sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Enrollment
1600
Locations
1
Primary Endpoint
Incidence of Breast Cancer
Status
Active, Not Recruiting
Last Updated
last year

Overview

Brief Summary

The goal of this multicentric prospective study is to evaluate the incidence of Breast Cancer in transgender and gender-diverse population.

Detailed Description

In recent years, the scientific community has been paying increasing attention to lesbian, gay, bisexual, transgender, queer, intersexual, asexual population, with a special focus on transgender and gender-diverse individuals. Globally, the percentage of adults who identify themselves as transgender varies between 0.3% and 0.5%, while approximately 0.5% to 4.5% of adults are estimated to identify as gender-diverse. Despite the growing visibility of transgender and gender-diverse community and the efforts towards their depathologization, healthcare still needs to address two fundamental issues: the inadequate preparation of healthcare staff regarding gender incongruence which results in mistreatment and discrimination and the lack of uniform and large-scale prospective data. Scientific evidence regarding the risk of developing breast cancer (BC) in these patients and the related benefits of BC screening are still limited and insufficient. The Associazione Italiana di Oncologia Medica (AIOM), reported that the risk of developing BC tends to increase in transgender women compared to cisgender men (standardized incidence ratio \[SIR\], 46.7; 95% CI, 27.2-75.4), although it does not reach the level of risk in cisgender women (SIR, 0.3; 95% CI, 0.2-0.4). Conversely, in transgender men, the risk of BC decreases when compared to cisgender women (SIR, 0.2; 95% CI, 0.1-0.5), but it still remains higher than the risk present in cisgender men (58.9; 95% CI, 18.7-142.2).As for the screening programs, there is a lower adherence among the transgender and non-conforming-gender population compared to the cisgender population, due to socio-economic barriers and a lack of clear recommendations supported by scientific evidence.The National Comprehensive Cancer Network (NCCN)and AIOM guidelines currently do not include specific recommendations for transgender individuals due to the aforementioned lack of scientific evidence. The American College of Radiology (ACR) regulates screening protocols for the transgender population based on factors such as age, hormone therapy exposure, surgical history, and risk categories.

Registry
clinicaltrials.gov
Start Date
May 1, 2024
End Date
March 31, 2026
Last Updated
last year
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Transgender and gender-diverse individuals ≥18 years old who meet the ACR inclusion criteria
  • Signed Informed Consent

Exclusion Criteria

  • Refuse to sign Informed Consent

Outcomes

Primary Outcomes

Incidence of Breast Cancer

Time Frame: 1 year

The incidence of BC in a selected population of transgender and gender-diverse individuals.

Secondary Outcomes

  • The adherence rate to the screening(1 year)

Study Sites (1)

Loading locations...

Similar Trials